GMP Grade IVT Enzymes for Therapeutic RNA Market Size and Revenue Impact Study 2025 to 2034

Report Id: 3248 Pages: 180 Last Updated: 16 December 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of the GMP-Grade IVT Enzymes for Therapeutic RNA Market

Global GMP-Grade IVT Enzymes for Therapeutic RNA Market- By Enzyme Type (IVT Workflow)

·         RNA Polymerases

o   T7 RNA Polymerase (dominant)

o   SP6 RNA Polymerase

o   T3 RNA Polymerase

·         Capping Enzymes

o   Vaccinia Capping Enzyme (Cap-0)

o   mRNA Cap 2′-O-Methyltransferase (Cap-1)

o   Alternative Viral Capping Enzymes (Faustovirus,etc)

·         Tailing Enzymes - Poly(A) Polymerase

·         Template Generation Enzymes

o   Restriction Endonucleases

o   High-fidelity DNA Polymerases

·         Cleanup / Yield / Protection

o   DNase I / dsDNase (RNase-free)

o   Inorganic pyrophosphatase

o   RNase inhibitor

·         Circular RNA Enzymes

o   T4 RNA Ligase I/II

o   RNase R

GMP-Grade IVT Enzymes for Therapeutic RNA Market

Global GMP-Grade IVT Enzymes for Therapeutic RNA Market – By RNA Modality

·         mRNA

·         saRNA/replicons

·         circRNA

·         gRNAs/crRNAs (CRISPR)

·         Other therapeutic RNAs (lncRNA/antisense where IVT is used)

Global GMP-Grade IVT Enzymes for Therapeutic RNA Market – By Application / Use Stage

·         GMP Drug Substance Manufacturing (Commercial)

·         GMP Clinical Supply & Process Development (Phase I–III)

·         Diagnostics/IVD (GMP-Qualified Enzymes Used in Regulated Kits)

·         Translational Research with GMP continuity (Pilot/Tech-transfer Lots)

Global GMP-Grade IVT Enzymes for Therapeutic RNA Market- By End User

·         Biopharma/Biotech sponsors (In-house Manufacturing)

·         CDMOs/CMOs

·         Diagnostics companies

·         Academic/Government Translational Centers

Global GMP-Grade IVT Enzymes for Therapeutic RNA Market – By Region

North America-

·         The US

·         Canada

Europe-

·         Germany

·         The UK

·         France

·         Italy

·         Spain

·         Rest of Europe

Asia-Pacific-

·         China

·         Japan

·         India

·         South Korea

·         Southeast Asia

·         Rest of Asia Pacific

Latin America-

·         Brazil

·         Mexico

·         Rest of Latin America

 Middle East & Africa-

·         GCC Countries

·         South Africa

·         Rest of the Middle East and Africa

 

Chapter 1.    Methodology and Scope
1.1.    Research Methodology
1.2.    Research Scope & Assumptions

Chapter 2.    Executive Summary

Chapter 3.    Global GMP-Grade IVT Enzymes for Therapeutic RNA Market Snapshot

Chapter 4.    Global GMP-Grade IVT Enzymes for Therapeutic RNA Market Variables, Trends & Scope
4.1.    Market Segmentation & Scope
4.2.    Drivers
4.3.    Challenges
4.4.    Trends 
4.5.    Investment and Funding Analysis 
4.6.    Porter's Five Forces Analysis
4.7.    Incremental Opportunity Analysis (US$ MN), 2024-2034 
4.8.    Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9.    Use/impact of AI on GMP-Grade IVT Enzymes for Therapeutic RNA Market Industry Trends 
4.10.    Global GMP-Grade IVT Enzymes for Therapeutic RNA Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034

Chapter 5.    GMP-Grade IVT Enzymes for Therapeutic RNA Market Segmentation 1: By Enzyme Type (IVT Workflow), Estimates & Trend Analysis
5.1.    Market Share by Enzyme Type (IVT Workflow), 2024 & 2034
5.2.    Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Enzyme Type (IVT Workflow):

5.2.1.    RNA Polymerases

5.2.1.1.    T7 RNA Polymerase (dominant)
5.2.1.2.    SP6 RNA Polymerase
5.2.1.3.    T3 RNA Polymerase

5.2.2.    Capping Enzymes

5.2.2.1.    Vaccinia Capping Enzyme (Cap-0)
5.2.2.2.    mRNA Cap 2′-O-Methyltransferase (Cap-1)
5.2.2.3.    Alternative Viral Capping Enzymes (Faustovirus,etc)

5.2.3.    Tailing Enzymes - Poly(A) Polymerase
5.2.4.    Template Generation Enzymes

5.2.4.1.    Restriction Endonucleases 
5.2.4.2.    High-fidelity DNA Polymerases 

5.2.5.    Cleanup / Yield / Protection

5.2.5.1.    DNase I / dsDNase (RNase-free)
5.2.5.2.    Inorganic pyrophosphatase
5.2.5.3.    RNase inhibitor

5.2.6.    Circular RNA Enzymes

5.2.6.1.    T4 RNA Ligase I/II
5.2.6.2.    RNase R

Chapter 6.    GMP-Grade IVT Enzymes for Therapeutic RNA Market Segmentation 2: By RNA Modality, Estimates & Trend Analysis
6.1.    Market Share by RNA Modality, 2024 & 2034
6.2.    Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following RNA Modality:

6.2.1.    mRNA
6.2.2.    saRNA/replicons
6.2.3.    circRNA
6.2.4.    gRNAs/crRNAs (CRISPR)
6.2.5.    Other therapeutic RNAs (lncRNA/antisense where IVT is used)

Chapter 7.    GMP-Grade IVT Enzymes for Therapeutic RNA Market Segmentation 3: By Application / Use Stage, Estimates & Trend Analysis
7.1.    Market Share by Application / Use Stage, 2024 & 2034
7.2.    Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application / Use Stage:

7.2.1.    GMP Drug Substance Manufacturing (commercial)
7.2.2.    GMP Clinical Supply & Process Development (Phase I–III)
7.2.3.    Diagnostics/IVD (GMP-qualified enzymes used in regulated kits)
7.2.4.    Translational Research with GMP continuity (pilot/tech-transfer lots)

Chapter 8.    GMP-Grade IVT Enzymes for Therapeutic RNA Market Segmentation 4: By End User, Estimates & Trend Analysis
8.1.    Market Share by End User, 2024 & 2034
8.2.    Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End User:

8.2.1.    Biopharma/Biotech sponsors 
8.2.2.    CDMOs/CMOs
8.2.3.    Diagnostics companies
8.2.4.    Academic/Government Translational Centers

Chapter 9.    GMP-Grade IVT Enzymes for Therapeutic RNA Market Segmentation 5: Regional Estimates & Trend Analysis
9.1.    Global GMP-Grade IVT Enzymes for Therapeutic RNA Market, Regional Snapshot 2024 & 2034
9.2.    North America

9.2.1.    North America GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

9.2.1.1.    US
9.2.1.2.    Canada

9.2.2.    North America GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by Enzyme Type (IVT Workflow), 2021-2034
9.2.3.    North America GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by RNA Modality, 2021-2034
9.2.4.    North America GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by Application / Use Stage, 2021-2034
9.2.5.    North America GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034

9.3.    Europe

9.3.1.    Europe GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

9.3.1.1.    Germany
9.3.1.2.    U.K.
9.3.1.3.    France
9.3.1.4.    Italy
9.3.1.5.    Spain
9.3.1.6.    Rest of Europe

9.3.2.    Europe GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by Enzyme Type (IVT Workflow), 2021-2034
9.3.3.    Europe GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by RNA Modality, 2021-2034
9.3.4.    Europe GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by Application / Use Stage, 2021-2034
9.3.5.    Europe GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034

9.4.    Asia Pacific

9.4.1.    Asia Pacific GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

9.4.1.1.    India 
9.4.1.2.    China
9.4.1.3.    Japan
9.4.1.4.    Australia
9.4.1.5.    South Korea
9.4.1.6.    Hong Kong
9.4.1.7.    Southeast Asia
9.4.1.8.    Rest of Asia Pacific

9.4.2.    Asia Pacific GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by Enzyme Type (IVT Workflow), 2021-2034
9.4.3.    Asia Pacific GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by RNA Modality, 2021-2034
9.4.4.    Asia Pacific GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by Application / Use Stage, 2021-2034
9.4.5.    Asia Pacific GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034

9.5.    Latin America

9.5.1.    Latin America GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

9.5.1.1.    Brazil
9.5.1.2.    Mexico
9.5.1.3.    Rest of Latin America

9.5.2.    Latin America GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by Enzyme Type (IVT Workflow), 2021-2034
9.5.3.    Latin America GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by RNA Modality, 2021-2034
9.5.4.    Latin America GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by Application / Use Stage, 2021-2034
9.5.5.    Latin America GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034

9.6.    Middle East & Africa 

9.6.1.    Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

9.6.1.1.    GCC Countries
9.6.1.2.    Israel
9.6.1.3.    South Africa
9.6.1.4.    Rest of Middle East and Africa

9.6.2.    Middle East & Africa GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by Enzyme Type (IVT Workflow), 2021-2034
9.6.3.    Middle East & Africa GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by RNA Modality, 2021-2034
9.6.4.    Middle East & Africa GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by Application / Use Stage, 2021-2034
9.6.5.    Middle East & Africa GMP-Grade IVT Enzymes for Therapeutic RNA Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034

Chapter 10.    Competitive Landscape
10.1.    Major Mergers and Acquisitions/Strategic Alliances
10.2.    Company Profiles


10.2.1.    New England Biolabs (NEB)

10.2.1.1.    Business Overview
10.2.1.2.    Key Enzyme Type (IVT Workflow)/Service Overview
10.2.1.3.    Financial Performance
10.2.1.4.    Geographical Presence
10.2.1.5.    Recent Developments with Business Strategy

10.2.2.    Thermo Fisher Scientific
10.2.3.    Roche CustomBiotech
10.2.4.    Merck KGaA (MilliporeSigma)
10.2.5.    Aldevron (Danaher/Cytiva)
10.2.6.    TriLink BioTechnologies (Maravai)
10.2.7.    Kactus Bio 
10.2.8.    Yeasen Biotech 
10.2.9.    Takara Bio 
10.2.10.    Canvax Biotech 
10.2.11.    LGC Biosearch Technologies 
10.2.12.    Novoprotein 
10.2.13.    Jena Bioscience 
10.2.14.    Baseclick GmbH 
10.2.15.    Tinzyme
10.2.16.    Promega Corporation 
10.2.17.    Kaneka Eurogentec 
10.2.18.    BOC Sciences 
10.2.19.    Creative Biogene 
10.2.20.    HONGENE  

 

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
1536
Security Code field cannot be blank!

Frequently Asked Questions

GMP-Grade IVT Enzymes for Therapeutic RNA Market Size is valued at USD 235.7 million in 2023 and is predicted to reach USD 391.9 million by the year 2034.

GMP-Grade IVT Enzymes for Therapeutic RNA Market is expected to grow at a 10.4% CAGR during the forecast period for 2025-2034.

GMP-Grade IVT Enzymes for Therapeutic RNA Market key players are New England Biolabs (NEB), Thermo Fisher Scientific, Roche CustomBiotech, Merck KGaA (MilliporeSigma), Aldevron (Danaher/Cytiva), TriLink BioTechnologies (Maravai), Kactus Bio, Yeasen Biotech, Takara Bio, Canvax Biotech, LGC Biosearch Technologies, Novoprotein, Jena Bioscience, Baseclick GmbH, Tinzyme, Promega Corporation, Kaneka Eurogentec, BOC Sciences, Creative Biogene, HONGENE

The GMP-grade IVT enzymes for the therapeutic RNA market are segmented into enzyme type (IVT workflow), RNA modality, application/use stage, and end user.

North America region is leading the GMP-Grade IVT Enzymes for Therapeutic RNA Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying